NEW YORK AND LONDON
Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, announced the first patient has been enrolled in its Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis.
A Revolution in Treating Autoinflammatory & Orphan Diseases